Drugs / alanosine
alanosine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00075894 | Mar 2004 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00062283 | Mar 2003 → Dec 2005 | lung cancer, malignant mesothelioma, malignant pancreatic neoplasm, sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alanosine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00075894 ↗ |
| Known as | Alanosina | ChEMBL registry synonym — accepted as the source's own label CHEMBL452715 ↗ |
| Known as | L-alanosine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00075894 ↗ |
| Known as | NSC-153353 | ChEMBL registry synonym — accepted as the source's own label CHEMBL452715 ↗ |
| Known as | NSC-529469 | ChEMBL registry synonym — accepted as the source's own label CHEMBL452715 ↗ |
| Known as | SDX-102 | “Patients receive alanosine (SDX-102) IV continuously for 5 days.” NCT00075894 ↗ |
| Modality | Small molecule | — CHEMBL452715 ↗ |
| Route | Intravenous | “Patients receive alanosine IV continuously on days 1-5.” NCT00062283 ↗ |